Phase I/II dose escalation, pharmacokinetic, safety, and efficacy study of oral TAC-101 [amsilarotene] in patients with advanced hepatocellular carcinoma.

Trial Profile

Phase I/II dose escalation, pharmacokinetic, safety, and efficacy study of oral TAC-101 [amsilarotene] in patients with advanced hepatocellular carcinoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Jul 2012

At a glance

  • Drugs Amsilarotene (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 27 Jul 2012 Additional lead trial centre and drug company added as reported by ClinicalTrials.gov.
    • 24 May 2010 Actual patient number (37) added as reported by ClinicalTrials.gov.
    • 24 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top